Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The primary one is competition from other GLP-1 drugs, especially from Eli Lillys Mounjaro (tirzepatide), which has shown greater efficacy in weight loss and diabetes control
The FDA has approved various GLP-1 receptor agonists for different indications, including glycemic control in type 2 diabetes and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
North Carolina Medicaid ended coverage of GLP-1s for obesity last month, citing shortfalls in state funding
3 The distinction matters for two reasons
:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)
US$ 24.21
US$ 27.45
US$ 28.92
